Journal Mobile Options
Table of Contents
Vol. 91, No. 2, 2013
Issue release date: August 2013

Role of Tramadol in Premature Ejaculation: A Systematic Review and Meta-Analysis

Yang L. · Qian S. · Liu H. · Liu L. · Pu C. · Han P. · Wei Q.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: This systematic review was performed to evaluate the efficacy and safety of tramadol in patients with premature ejaculation (PE). Methods: A systematic search of PubMed®, Embase® and the Cochrane Library was performed to identify all randomized controlled trials (RCTs) that compared the effects of tramadol with placebo or no drug for patients with PE. The outcomes included post-therapeutic intravaginal ejaculation latency time (IELT), increases in IELT, satisfaction with sexual intercourse, control over ejaculation and side effects (SEs). The Cochrane Collaboration Review Manager software (RevMan 5.1.4) was used for statistical analysis. Results: A total of 5 trials, involving 715 patients, met the inclusion criteria. The synthesized data from these RCTs indicated that compared with the control, tramadol significantly increased IELT values post-therapeutically (SMD 3.51, 95% CI 2.14-4.88, p < 0.00001) and changes in IELT values were more pronounced in the tramadol group (SMD 2.87, 95% CI 2.63-3.10, p < 0.00001). Satisfaction with sexual intercourse and the ability to control ejaculation were both improved in patients in the tramadol group (p < 0.05). The incidence of SEs in the tramadol group were significantly higher than in the control group (RR 3.55, 95% CI 1.34-9.40, p = 0.01), however most SEs were mild or moderate and transient. Conclusions: Tramadol may be effective in PE treatment, especially when patients have failed therapies, like selective serotonin reuptake inhibitors. However, the possibility of drug addiction and SEs should still be considered before initial use or after chronic use of this agent. More high-quality (clear randomization sequences, allocation concealment and blinding introduction), long-term, RCTs with a large number of PE patients are expected. © 2013 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bejma JP, Hellstrom WJG: Premature ejaculation. Am Urol Assoc Update Series 2007;26:365-371.
  2. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E; European Association of Urology: Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-814.
  3. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J: The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007;51:816-824.
  4. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, et al: An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med 2008;5:1590-1606.
  5. Morales A, Brada J, Wyllie MG: A review of the current status of topical treatments for premature ejaculation. BJU Int 2007;100:493-501.
  6. Althof SE: Psychological treatment strategies for rapid ejaculation: rationale, practical aspects, and outcome. World J Urol 2005;23:89-92.
  7. Safarinejad MR, Hosseini SY: Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006;26:27-31.
  8. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA: Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med 2008;5:188-193.
  9. Xiong G, Wu F, Chen S, Yao W: Safety and efficacy of tramadol hydrochloride with behavioral modification in the treatment of premature ejaculation (in Chinese). Zhonghua Nan Ke Xue 2011;17:538-541.

    External Resources

  10. Kaynar M, Kilic O, Yurdakul T: On-demand tramadol hydrochloride use in premature ejaculation treatment. Urology 2012;79:145-149.
  11. Bar-Or D, Salottolo KM, Orlando A, Winkler JV: A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 min. Eur Urol 2012;61:736-743.
  12. Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud el-HM, Amr M: Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. J Sex Med 2010;7:2860-2867.
  13. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
  14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
  15. Rosen RC, Althof S: Impact of premature ejaculation: the psychological, quality of life and sexual relationship consequences. J Sex Med 2008;5:1296-1307.
  16. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B: Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004;16:3369-3381.
  17. Montague DK, Jarow J, Broderick G, Dmochowski RR, Heaton JP, Lue TF, et al: AUA Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004;172:290-294.
  18. Sadeghi-Nejad H, Watson R: Premature ejaculation: current medical treatment and new directions. J Sex Med 2008;5:1037-1050.
  19. Mulhall JP: Current and future pharmacotherapeutic strategies in treatment of premature ejaculation. Urology 2006;67:9-16.
  20. Giuliano FA: Tramadol for the treatment of premature ejaculation. Eur Urol 2012;61:744-745.
  21. Ho CC: Re: David Bar-Or, Kristin M. Salottolo, Alessandro Orlando, James V. Winkler. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol 2012;61:e23-e24.
  22. Palmer NR: Tramadol for premature ejaculation. J Sex Med 2009;6:294-299.
  23. Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, et al: A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006;31:465-476.
  24. McMahon CG, Porst H: Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent international society for sexual medicine criteria for lifelong premature ejaculation. J Sex Med 2011;8:2707-2725.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50